831
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of selected indigenous medicinal plants from the western Himalayas for cytotoxicity and as potential cancer chemopreventive agents

, , , , , , & show all
Pages 533-538 | Received 10 Jun 2008, Accepted 12 Aug 2008, Published online: 01 Jun 2009

Abstract

The western Himalayas in the northern areas of Pakistan have significant potential for ethnomedicinal research. In the current study, indigenous informants were interviewed using open-ended questionnaires and a free-listing of knowledge related to native medicinal plants. Information patterns indicated that over 100 local plant species were in frequent medicinal use for a variety of conditions, including inflammation and cancer. Several field surveys were conducted in community forests and meadows, with the aim of exploration, collection, taxonomic identification, and finally, in vitro analysis. Organic extracts of eight species were tested for inhibition of nuclear factor-kappaB (NF-κB), activation of retinoic acid X receptor alpha (RXR), induction of quinone reductase (QR), and inhibition of aromatase, along with assessment of cytotoxicity with four human cancer cell lines. Mellia azedarach, Ajuga bractiosa, Figonia cretica and Swertia chirata inhibited both tetradecanoylphorbol-13-acetate (TPA) and tumor necrosis factor (TNF) activated NF-κB activity, whereas Silybum merianum and Rumex dentatus were only active against TNF activation. The lowest IC50 values for inhibition of TPA activated NF-κB activity were 0.41 and 0.44 μg/mL for A. bractiosa and S. chirata, respectively. Extracts from three plant species, A. bractiosa, R. dentatus and R. hastaus, were active in the RXR assay. Results from the QR assay showed five active samples (with induction ratios >2) belonging to four species: A. bractiosa, R. dentatus, S. merianum and S. chirata. Most of the plant extracts were not cytotoxic (IC50 values >20 μg/mL) with HepG2, MCF7, LNCaP and LU cell lines. Only two plants, R. dentatus and R. hastaus, demonstrated moderate cytotoxic responses (IC50 values 5-15 μg/mL) with HepG2, MCF7 or LNCaP cells. None of the plant extracts was found to inhibit aromatase activity. Based on these data, it may be suggested that the plants under investigation contain potential chemopreventive compounds. Additional testing is required. However, the positive responses observed in these bioassays illustrate the high potential of local medicinal plants.

Introduction

Indigenous people in different parts of the world have a common tendency for dependence on medicinal plants growing in their surrounding areas (CitationShinwari et al., 2000). Skills have been learned and developed over centuries, which impact their diverse and independent systems of medicine. Some herbal preparations are reported to have enormous potential for the cure of both simple and complex ailments (CitationSalick et al., 1999). The geographic region currently under investigation, situated in the Himalayan and Karakorum mountain ranges, shares a large number of medicinal plants as a result of remarkable flora. Further, the local system of medicine and cultural use of plants make this area of value for the identification of medicinal species and ethnomedicinal research (CitationGoodman & Ghafoor, 1992). In addition, it is worth noting that some plant-based medicines which are frequently used by the native people to cure simple ailments also protect from more complex diseases (CitationQureshi & Ghufran, 2005; CitationPezzuto et al., 2006).

In spite of improved treatment options, many of which are plant-based (CitationPezzuto et al., 2005; CitationWeinstein, 1991), cancer is still one of the leading causes of death in the world. In addition to being of value for cancer therapy, natural products are known to serve as a useful source of cancer chemopreventive agents (CitationKondratyuk & Pezzuto, 2004; CitationSharma et al., 1994; CitationBoone et al., 1990; CitationSchatzkin et al., 1990). In searching for new therapeutic or preventative modalities, it is worth considering various indigenous medicinal preparations that have been reported by native people and herbalists as effective cancer treatments. These medicinal plants also include several foods, seasonings, spices and condiments in everyday use by indigenous communities (CitationWeinstein, 1991). It is possible that regular use of these plants could reduce the incidence of cancer by inhibiting the process of carcinogenesis (CitationPezzuto et al., 2006; CitationWattenberg, 1985; CitationDorai & Aggarwal, 2004).

Following a detailed field survey involving free-listings and questionnaire-based data collection, we selected eight plant species used most frequently in the Himalayas, and tested them for cancer chemopreventive activity with in vitro models. Nearly all of the test species were found to be active in one or more of the selected assays. Accordingly, these native remedies may represent sources for the discovery of new chemopreventive agents. Equally important, the results illustrate the value of focused selection based on traditional knowledge.

Materials and methods

Collection of plant material

Plant collection was carried out from the spring of 2004 to the autumn of 2006 in several valleys and villages of an administrative region of Pakistan (called the “northern areas” of Pakistan), situated between 72°32 to 76°56 east longitudes and 35°11 to 37°05 north latitudes (CitationGhufran et al., 2007). Most of the sampling was performed between the Diamer and Skardu Districts. All of the field studies were conducted in close association with local communities to collect medicinal plants from each community’s forest reserves and high altitude pastoral lands. Exploration trips were conducted in different parts of the year in order to collect traditional medicinal plants at their appropriate harvest time. Data concerning the traditional uses of these plant species was collected using semi-structured and open-ended questionnaires, as well as field notes regarding the local traditions for harvest, processing and indigenous use. Informants were also requested to provide a listing of medicinal plants in use in their community, along with the known benefits of each species.

Collection, preservation and taxonomic identification were carried out by comparing each specimen with existing voucher specimens from various herbaria in Pakistan. These samples were then mounted and deposited in the Herbarium of Pakistan (ISL), at the Department of Plant Sciences Quaid-i-Azam University, Islamabad, Pakistan (Accession numbers 124118 to 125010, including the duplicates for each specimen to be used for future analytical work).

In this survey, 135 plant species with reported medicinal value were collected. Data from the questionnaires and free-listings were compiled in order to identify the most promising species for chemoprevention. Based on the frequency, pattern, and methods of using these plants, eight species were selected for testing in cancer chemoprevention and cytotoxicity assays.

Preparation of extracts

Plants were extracted in various solvents and different parts were tested individually for activity (). Shade-dried plant materials were crushed in small sections (500 g each) and soaked for three days using methanol as the solvent. Plant material was then filtered out and used for further extraction. Three consecutive extractions were collected and the plant residues were discarded.

Table 1. Taxonomic data of plants selected for biological screening.

The solvent was evaporated using a rotary evaporator. Some of the crude extract was retained while the remainder was further partitioned into polar and non-polar fractions using hexane and chloroform. The remaining water fraction was not tested.

Biological assays

Several assays were performed to test the cancer chemopreventive activity of the plant extracts. The in vitro assays included nuclear factor-kappaB (NF-κB) (Homhual et al., 2006; CitationDorai & Aggarwal, 2004), quinone reductase (QR) (CitationCuendet et al., 2006), aromatase (CitationStrasser-Weippl & Goss, 2005), retinoic X receptor alpha (RXR) (CitationWu et al., 2002), and assessment of cytotoxicity (CitationMi et al., 2001). Cytotoxicity was assessed with four different human cancer cell lines, namely, hepatocellular carcinoma ATCC number HB-8065 (HepG2), mammary adenocarcinoma ATCC number HTB-22 (MCF-7), prostate lymph node carcinoma ATCC number CRL-1740, (LNCaP) and lung carcinoma cells (LU) established at the Department of Surgical Oncology, University of Illinois at Chicago. For the screening of potential chemopreventive agents, in vitro short-term tests were preferred because they are less time-consuming and more reliable. A brief description of each assay is given below.

NF-κB assay

The 293/NF-κB-Luc cell line, designed for monitoring the activity of the NF-κB (CitationHomhual et al., 2006), was purchased from Panomics (Freemont, CA). Cells were seeded into sterile white-walled 96-well plates at 20 × 103 cells per well in Dulbecco’s modified media with 10% fetal bovine serum (FBS). After growing for 48 h to 90% confluency, the medium was replaced with fresh medium containing tetradecanoylphorbol-13- acetate (TPA) (final concentration 100 nM) or tumor necrosis factor (TNF) (final concentration 50 ng/mL) simultaneously with different test extracts (at a final concentration of 20 μg/mL), followed by 6 h incubation. Luciferase activity was determined with a luciferase kit from Promega (Madison, WI) according to the manufacturer’s instructions. Briefly, after treatment, the cells were washed with phosphate-buffered saline and 1x Reporter lysis buffer was added before plates were placed in a -80°C freezer. The following day the cells were thawed and assayed for luciferase activity with a LUMIstar Galaxy Luminometer (BMG Labtechnologies, Durham, NC).

RXR ligand binding assay

The LanthaScreen TR-FRET RXR alpha Coactivator Assay from Invitrogen (Carlsbad, CA) was used according to the manufacturer’s protocol. Test samples were mixed in a black 384-well plate with a fluorescein labeled PGC1-alpha coactivator peptide, a terbium labeled anti-GST antibody, and the GST-labeled ligand binding domain (LBD) of RXR alpha. After 1 h incubation with shaking at room temperature, plates were read in a Synergy 2 fluorescent plate reader (Biotek, Winooski, VT). Each well was excited at 340 nm and emissions were read at 520 nm (to detect fluorescent resonance energy transfer (FRET)) and 490 nm (to detect terbium background). Binding of test sample to RXR LBD caused a conformational change in the RXR, resulting in binding of both the fluorescein-PGC1-alpha coactivator peptide and the terbium anti-GST antibody. The close proximity of the fluorescein and terbium tags resulted in a time-resolved FRET signal at 520 nm. Assay output was measured as the ratio of 520:495 emissions. Each sample was additionally tested to ensure it did not autofluoresce in the emission ranges used in this assay.

Quinone reductase assay

Quinone reductase was assessed in 96-well plates using Hepa 1c1c7 murine hepatoma cells as previously reported (CitationSong et al., 1999). Briefly, cells were grown to a density of 2 × 104 cells/mL in 200 μL of minimal essential medium (MEM)-α containing 5% antibiotic-antimycotic (Gibco) and 10% fetal bovine serum at 37°C in 5% CO2 atmosphere. After 24 h preincubation, the media was changed and test compounds were added to a final concentration of 20 μg/mL. For dose dependence, samples were added in five serial three-fold dilutions. The cells were incubated with test samples for an additional 48 h. Quinone reductase activity was measured as a function of the NADPH-dependent menadiol-mediated reduction of 3-(4,5-dimetylthiazo-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to a blue formazan (CitationKennelly et al., 1997). Protein content was determined via crystal violet staining of identical plates. Specific activity is defined as nmol of formazan formed per mg protein per min (CitationProchaska & Santamaria, 1988). The induction ratio (IR) of QR activity represents the specific enzyme activity of agent-treated cells compared with a DMSO-treated control. The concentration to double activity (CD) was determined through a dose-response assay for active substances (IR >2).

Aromatase assay

Aromatase activity was assayed as previously reported (CitationMaiti et al., 2007) with the necessary modifications to perform the test in 384-well plates. The test substance (3.5 μL) was preincubated with 30 μL of NADPH regenerating system (2.6 mM NADP+, 7.6 mM glucose 6-phosphate, 0.8 U/mL glucose 6-phosphate dehydrogenase, 13.9 mM MgCl2, and 1 mg/mL albumin in 50 mM potassium phosphate buffer, pH 7.4) for 10 min. The enzyme and substrate mixture (33 μL of 80 μL/mL enzyme (CYP19, BD Biosciences, San Jose, CA), 0.4 μM dibenzylfluorescein, and 4 mg/mL albumin in 50 mM potassium phosphate, pH 7.4) was added and the plate was incubated for 30 min at 37°C before quenching with 25 μL of 2 N NaOH. After termination of the reaction and shaking for 5 min, the plate was further incubated for 2 h at 37°C. This enhances the ratio of signal to background. Fluorescence was measured at 485 nm (excitation) and 530 nm (emission).

Cytotoxicity analysis

The cytotoxic potential of test substances was determined with HepG2, MCF-7, LNCaP and LU cells were assessed as described previously (CitationYou et al., 1995; CitationMi et al., 2001). Cells were seeded in 96-well plates (106 cells/mL), and various concentrations of samples dissolved in 10 μL of 10% DMSO were added to each well. The plates were incubated for 72 h at 37°C and cell viability was determined with sulforhodamine B staining. The IC50 values were determined as the concentration of sample required to inhibit the 72 h growth of cells by 50%, relative to a control treated with solvent (0.5% DMSO) only.

Results and discussion

Of 135 plant species with traditional medicinal uses collected, eight were selected for assays to determine cancer chemopreventive activity. These species included Ajuga bractiosa, Hippophae rhamnoides subsp. turkestanica, Figonia cretica, Melia azedarach, Rumex dentatus, Rumex hastaus, Swertia chirata and Silybum marianum. Only those portions of selected species which are used in local medicinal preparations were chosen for extraction. For example, only leaves of M. azedarach and A. bracteosa are used locally, while all parts of R. dentatus and S. marianum are used medicinally. denotes the origin of each test fraction.

NF-κB is an inducible factor for gene transcription involved in cell survival (CitationChen et al., 2001), cell adhesion and differentiation, inflammation, and cell and tissue growth (CitationBharti & Aggarwal, 2002). In healthy cells, NF-κB is present in the cytoplasm and binds to the inhibitory IκB protein, which blocks the nuclear localization sequences of NF-κB (CitationDorai & Aggarwal, 2004). A number of genes which are involved in tumor cell invasion and angiogenesis have been found to be regulated by NF-κB. Activation of NF-κB supports cell survival and proliferation, while down-regulation of NF-κB sensitizes the cell to apoptosis. There is a need to search for specific inhibitors from new sources like indigenous medicinal plants. Therefore, organic extracts of all species were tested in the NF-κB assay activated by two different activators, TPA or TNF. Extracts of M. azedarach, A. bractiosa, F. cretica and S. chirata were found to be active (sample numbers 2, 6, 7, 8 and 20) in inhibiting both TPA and TNF activated NF-κB assays, whereas S. marianum and R. dentatus (sample numbers 14, 15 and 16) were only active in the TNF activated NF-κB assay (). Out of the available IC50 values, the lowest were 0.41μg/mL and 0.44μg/mL for A. bractiosa and S. chirata, respectively (), which validate the higher potential of these plants as candidates for chemoprevention (CitationDorai & Aggarwal, 2004, CitationGoodman, 1992). As demonstrated previously (CitationRiaz et al., 2007), components of A. bracteosa also inhibit lipoxygenase activity.

Table 2. Activity of plant samples determined with in vitro assays for NF-κB, RXR and QR activity.

Retinoids are derivatives of vitamin A which influence cellular proliferation, differentiation, and apoptosis in a retinoid-specific and cell-type specific manner. Retinoids have shown efficacy as anti-cancer drugs that intervene in the carcinogenic process by regulating proliferation and differentiation at several stages (CitationWu et al., 2002; CitationConley et al., 1998). Retinoid receptors are nuclear hormone receptor proteins. There are two major classes of retinoid nuclear receptors: retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Compounds that are specific ligands of RXR have been shown to cause cancer cells to differentiate, which limits their potential to proliferate. RXR specific ligands exhibit less toxicity as compared to ligands of RAR receptors. For this reason, we screened our test samples to determine if they could bind to RXR. Only three plant species, A. bractiosa, R. dentatus and R. hastaus, were active in the RXR binding assay and therefore were considered significant for future screening. The results were normalized to the negative control (4% DMSO) condition, which yielded a coactivator recruitment score (CRS) of 1. Positive control, 9-cis-retinoic acid, gave a CRS of 2.73. Samples with a CRS above 1.2 were tested for dose dependence. Four samples with the highest CRS yielded EC50 values in the low μg/mL range. All other samples showed no activity.

Samples were also tested for induction of QR. Quinone reductase is an important phase II enzyme that deactivates reactive and potentially carcinogenic species (CitationCuendet et al., 2006) by converting quinones to hydroquinones and reducing oxidative cycling. The QR enzyme exhibits a broad specificity, reducing a wide range of hydrophobic quinones of various structures (CitationBenson et al., 1980). The induction of QR often coincides with induction of other phase II enzymes, and is therefore useful in the study of potential chemopreventive agents. Five samples were found to induce QR (with IR values >2). These fractions (6, 7, 12, 19 and 20) represent four species: A. bractiosa, R. dentatus, S. merianum and S. chirata. Fraction 20 (S. chirata) is especially noteworthy, with a CD of 0.42 μg/mL.

None of the tested plant extracts developed inhibition of aromatase activity. Importantly, most of the plant extracts were not cytotoxic when tested at 20 μg/mL with HepG2, MCF-7, LNCaP and LU cell lines. Only R. dentatus and R. hastaus demonstrated cytotoxic effect with HepG2 cells (IC50 12.99 and 15.29 μg/mL), MCF-7 cells (IC50 5.1 and 12.54 μg/mL) and LNCaP cells (IC50 14.86 and 15.53 μg/mL, respectively) while for LU cells there was no cytotoxic effect observed (CitationYou et al., 1995). These data provide some insight for the prospective use of the tested plant species in cancer research (CitationLippman et al., 1990). Studies are still in progress for further screening of active components from these species.

Conclusions

With the exception of Hippophae rhamnoides subsp. tukrestanica, all of the plant species tested were found to be active in one or more of the assays reported herein. Since approximately 50% (11 samples) of the test substances were active, either the method of extraction or plant part affects the results. Two plants species, A. bractiosa and S. chirata, were active in NF-κB, RXR, as well as QR assays, and they did not display cytotoxicity, indicating they may represent a promising source of chemopreventive agents that can be identified through the process of bioassay-directed fractionation. In sum, the results of this study demonstrate the chemopreventive potential of local medicinal plants and the merit of working with indigenous communities.

Acknowledgements

The authors are grateful for funding support by the Higher Education Commission Pakistan, under “International Research Support Initiative Program” for field survey. We also acknowledge all the local people, herbalists and field staff for their help during plant collection. This work was supported by Program Project P01 CA48112 USA, awarded by the National Cancer Institute, USA.

This work was presented in part as an abstract at the 31st Annual Conference of the American Society of Ethnobiology, University of Arkansas, Fayetteville, Arkansas, USA, 16–19 May 2008.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

  • Benson AM, Hunkeler MJ, Talalay P (1980): Increase of NAD(P)H: quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 77: 5216–5220.
  • Bharti AC, Aggarwal BB (2002): Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64: 883–888.
  • Boone CW, Kelloff GJ, Malone WE (1990): Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 50: 2–9.
  • Chen F, Castranova V, Shi XL (2001): New insights into the role of nuclear factor-kappa B in cell growth regulation. Am J Pathol 159: 387–397.
  • Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, Fram RJ, Van Echo DA (1998): Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 4: 629–634.
  • Cuendet M, Oteham CP, Moon RC, Pezzuto JM (2006): Quinone reductase induction as a biomarker for cancer chemoprevention. J Nat Prod 69: 460–463.
  • Dorai T, Aggarwal BB (2004): Role of chemopreventive agents in cancer therapy. Cancer Lett 215: 129–140.
  • Ghufran MA, Ghaffar SA, Qureshi RA (2007): Ethnobotanical study of the alpine-subalpine flora of Neelum Valley, Azad Jammu and Kashmir. Pak J Sci Ind Res 50: 278–283.
  • Goodman GE (1992): The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives. Cancer Res 52: 2752–2757.
  • Goodman SM, Ghafoor A (1992): The ethnobotany of southern Baluchistan, Pakistan, with particular reference to medicinal plants. Fieldiana Bot 31(5): 1–84.
  • Homhual S, Bunyapraphatsara N, Kondratyuk TP, Herunsalee A, Chaukul W, Pezzuto JM, Fong HHS, Zhang HJ (2006): Bioactive dammarane triterpenes from the mangrove plant Bruguiera gymnorrhiza. J Nat Prod 69, 421–424.
  • Kennelly EJ, Gerhäuser C, Song LL, Graham JG, Beecher CWW, Pezzuto JM, Kinghorn AD (1997): Induction of quinone reductase by withanolides isolated from Physalis philidelphica (tomatillos). J Agri Food Chem 45: 3771–3777.
  • Kondratyuk T, Pezzuto JM (2004): Natural product polyphenols of relevance to human health. Pharm Biol 42: 46–63.
  • Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK (1990): Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 82: 555–560.
  • Maiti A, Cuendet M, Croy VL, Endringer DC, Pezzuto JM, Cushman M (2007): Synthesis and biological evaluation of (±)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. J Med Chem 50: 2799–2806.
  • Mi Q, Cui B, Silva GL, Lantvit D, Lim E, Chai H, You M, Hollingshead MG, Mayo JG, Kinghorn AD, Pezzuto JM (2001): Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Cancer Res 61: 4030–4037.
  • Pezzuto JM, Kosmeder JW, Park EJ, Lee SK, Cuendet M, Gills J, Bhat K, Grubjesic S, Park HS, Mata-Greenwood E, Tan YM, Yu R, Lantvit DD, Kinghorn AD (2005): Characterization of natural product chemopreventive agents, in: G.J. Kelloff, E.T. Hawk, and C.C. Sigman (eds.) Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention. Totowa, NJ, Humana Press, pp. 1–37.
  • Pezzuto JM, Kondratyuk TP, Shalaev E (2006): Cancer chemoprevention by wine polyphenols and resveratrol, in: W. Baer-Dubowska, A. Bartoszek, and D. Malejka-Giganti (eds.), Carcinogenic and Anticarcinogenic Food Components, Chapter 12. Boca Raton, FL, CRC Press, Taylor and Francis Group, pp. 239–258.
  • Prochaska HJ, Santamaria AB (1988): Direct measurement of NAD(P)H: quinine reductase from cells in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 169: 328–336.
  • Qureshi RA, Ghufran MA (2005): Medicinal value of some important roses and allied species of northern areas of Pakistan, in: Hashmi M, ed., Pakistan Rose Annual, Islamabad, Pictorial Printers, pp. 24–29.
  • Riaz N, Nawaz SA, Mukhtar N, Malik A, Afza N, Ali S, Ullah S, Muhammad P, Choudhary MI (2007): Isolation and enzyme-inhibition studies of the chemical constituents from Ajuga bracteosa. Chem Biodivers 4: 72–83.
  • Salick J, Biun A, Martin G, Apin L, Beaman R (1999): Whence useful plants? A direct relationship between biodiversity and useful plants among the Dusun of Mt. Kinabalu. Biodiv Conserv 8: 797–818.
  • Schatzkin A, Freedman LS, Schiffman MH, Dawsey SM (1990): Validation of intermediate end points in cancer research. J Natl Cancer Inst 82: 1746–1752.
  • Sharma S, Stutzman JD, Kelloff GJ, Steele VE (1994): Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res 54: 5848–5855.
  • Shinwari ZK, Watanabe T, Yousaf Y (2000): Medicinal plants of Pakistan: an overview, in: Proceedings of Nepal-Japan Joint Symposium on Conservation of Natural Medicinal Resources and their Utilization, Kathmandu, Nepal, 5-11 November 2000, pp. 279–285.
  • Song LL, Kosmeder JW, Lee SK, Gerhauser C, Lantvit D, Moon RC, Moriarty RM, Pezzuto JM (1999): Cancer chemopreventive activity mediated by 49-bromoflavone, a potent inducer of phase II detoxification enzymes. Cancer Res 59: 578–585.
  • Strasser-Weippl K, Goss PE (2005): Counteracting estrogen as breast cancer prevention, in: G.J. Kelloff, E.T. Hawk, and C.C. Sigman (eds.) Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention. Totowa, NJ, Humana Press, pp. 249–264.
  • Wattenberg LW (1985): Chemoprevention of cancer. Cancer Res 45: 1–8.
  • Weinstein IB (1991): Cancer prevention: recent progress and future opportunities. Cancer Res 51: 5080–5085.
  • Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH (2002): Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomark Prev 11: 467–474.
  • You M, Wickramaratne DB, Silva GL, Chai H, Chagwedera TE, Farnsworth NR, Cordell GA, Kinghorn AD, Pezzuto JM (1995): Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells. J Nat Prod 58: 598–604.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.